SSY Group's drotaverine hydrochloride gets China regulatory approval

SSY Group Limited announced that its drotaverine hydrochloride product has received approval for registration from the National Medical Products Administration of China.

The approval designates the drug as a bulk drug ready for market preparations. Drotaverine hydrochloride is an antispasmodic medication primarily used to treat spasms in the biliary, urinary, and gastrointestinal tracts.